2017 / 05

Next Paper
DOI: 10.24075/brsmu.2017-05-06

ORIGINAL RESEARCH

The role of immunological memory in establishing antitumor immunity in patients with ovarian cancer undergoing neoadjuvant therapy

Zlatnik EYu1, Nerodo GA2, Ardzha AYu2, Seliutina ON1, Bondarenko ES1
About authors

1 Laboratory for Immunophenotyping of Tumors,
Rostov Research Institute of Oncology, Rostov-on-Don, Russia

2 Department of Gynecologic Oncology,
Rostov Research Institute of Oncology, Rostov-on-Don, Russia

Correspondence should be addressed: Elena Zlatnik
14-ya liniya, d. 63, Rostov-on-Don, Russia, 344037; ur.liam@kintalz-anele

About paper

Contribution of the authors to this work: Zlatnik EYu — processing and analysis of results of immunological tests, drafting of a manuscript, correspondence with editors; Nerodo GA — research planning, medical supervision, surgical operations and treatment of the patients, data analysis and interpretation; Ardzha AYu — analysis of literature, data collection and analysis, medical supervision; Seliutina ON, Bondarenko ES — immunological tests.

Received: 2017-09-22 Accepted: 2017-09-30 Published online: 2018-01-14
|
  1. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther. 2009 Jun; 9 (6): 677–88. DOI: 10.1517/14712590902932897.
  2. Golubovskaya V, Wu L. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. Cancers (Basel). 2016 Mar 15; 8 (3): pii: E36. DOI: 10.3390/cancers8030036.
  3. Beckhove Ph, Feuerer M, Dolenc M, Schuetz F, Choi C, Sommerfeldt N, et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest. 2004 Jul 1; 114 (1): 67–76. DOI: 10.1172/JCI200420278.
  4. Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, et al. A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response. J Immunol. 2000 Dec 1; 165 (11): 6644–52. DOI: 10.4049/jimmunol.165.11.6644.
  5. Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, et al. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 2002 Mar 15; 62 (6): 1743–50.
  6. Hadrup S, Donia M, Thor Straten P. Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment. Cancer Microenviron. 2013 Aug; 6 (2): 123–33. DOI: 10.1007/s12307-012-0127-6.
  7. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005 Jul 5; 102 (27): 9571–6.
  8. Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naive, effector, and memory CD8 (+) T cells. J Exp Med. 2001 Oct 1; 194 (7): 953–66.
  9. Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003 Mar; 4 (3): 225–34.
  10. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999 Oct 14; 401 (6754): 708–12.
  11. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004; 22: 745–63.
  12. Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol. 2014 Jan; 44 (1): 69–79. DOI: 10.1002/eji.201343718.
  13. Perret R, Ronchese F. Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens. 2008 Sep; 72 (3): 187–94. DOI: 10.1111/j.1399-0039.2008.01088.x.
  14. Shin H, Iwasaki A. Tissue-resident memory T cells. Immunol Rev. 2013 Sep; 255 (1): 165–81. DOI: 10.1111/imr.12087.
  15. Zammit DJ, Turner DL, Klonowski KD, Lefrançois L, Cauley LS. Residual antigen presentation after influenza virus infection affects CD8 T cell activation and migration. Immunity. 2006 Apr; 24 (4): 439–49.
  16. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012 Nov 15; 491 (7424): 463–7. DOI: 10.1038/nature11522.
  17. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A. 2012 May 1; 109 (18): 7037–42. DOI: 10.1073/pnas.1202288109.
  18. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011 Apr; 3 (4): 539–56. DOI: 10.2217/imt.11.20.
  19. de Bruyn M, Wiersma VR, Wouters MC, Samplonius DF, Klip HG, Helfrich W, et al. CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. Oncoimmunology. 2015 Mar 19; 4 (4): e999536. eCollection 2015 Apr. DOI: 10.1080/2162402X.2014.999536.
  20. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004 Jul; 4 (7): 540–50. DOI: 10.1038/nrc1388.
  21. Berezhnaya NM, Chekhun VF. Immunologiya zlokachestvennogo rosta. Kiev: Naukova Dumka; 2005. 792 p. Russian.
  22. Fidler IJ. The organ microenvironvent and cancer metastasis. Differentiation. 2002 Dec; 70 (9–10): 498–505.
  23. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvirontments. Cancer Res. 2006 Jan 15; 66 (2): 605–12.
  24. Ashrafyan LA, Kiselev VI, Muizhnek EL, Gerfanova EV, Antonova IB, Kuznetsov IN, et al. [Current principles of effective therapy for ovarian cancer.] Opukholi zhenskoy reproduktivnoy sistemy. 2015; 11 (2): 68–75. Russian.
  25. Tyulyandin SA, Den'gina NV, Kolomiets LA, Morkhov KYu, Nechushkina VM, Pokataev IA, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu raka yaichnikov/ pervichnogo raka bryushiny/ raka matochnykh trub. Zlokachestvennye opukholi. 2016; (4 Suppl 2): 123–34. Russian.
  26. Shmelev VA, Lichinitser MR, Abramov ME, Kuznetsov VV, Slavina EG, Kadagidze ZG. Innovatsionnyy protivoopukholevyy tsitokinovyy preparat Ingaron. Meditsinskiy alfavit. Diagnosticheskaya radiologiya i onkoterapiya. 2013; (3–4): 60–8. Russian.
  27. Nerodo GA, Novikova IA, Zlatnik EYu, Ardzha AYu. [Application of Ingaron in combination with chemotherapy in patients with stage III–IV ovarian cancer]. Fundamental'nye issledovaniya. 2015; (1–8): 1649–54. Russian.
  28. Bryuzgin VV, Platinskij LV. [The role of cytokines in the chemotherapy of malignant tumors: the practice of cytokines Refnot and Ingaron administration in advanced cancer with multiple metastases]. Sovremennaya onkologiya. 2014; 16 (1): 70–5. Russian.
  29. Zlatnik EYu, Nerodo GA, Novikova IA, Bakhtin AV, Zakora GI, Selyutina ON, et al. [Molecular and cellular factors of local immunity in ascitic fluid of ovarian cancer patients]. Molekulyarnaya meditsina. 2016; 14 (3): 39–42. Russian.
  30. Pollard JW. Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer. 2004 Jan; 4 (1): 71–8.
  31. Kurganova EV, Tikhonova MA, Lebedeva VA, Laskavaya EG, Kovalenko VF, Ostanin AA, et al. [Regulatory T-cells in ovarian cancer]. Sibirskiy onkologicheskiy zhurnal. 2008; 30 (6): 40–5. Russian.
  32. Laskavaya EG, Lebedeva VA, Narov YuI, Tikhonova MA, Kurganova EV, Ostanin AA, et al. Regulyatornye CD4+ i CD8+ kletki u bol'nykh s dobrokachestvennymi i zlokachestvennymi obrazovaniyami yaichnikov. Sibirskiy onkologicheskiy zhurnal. 2010; (Suppl 1): 67–8. Russian.
  33. Chu T, Tyznik AJ, Roepke S, Berkley AM, Woodward-Davis A, Pattacini L, et al. Bystander-activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner. Cell Rep. 2013 Mar 28; 3 (3): 701–8. doi: 10.1016/j.celrep.2013.02.020
  34. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005 Dec 22; 353 (25): 2654–66.
  35. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014 Jun; 20 (6): 607–15. DOI: 10.1038/nm.3541.
  36. Nerodo GA, Zlatnik EYu, Novikova IA, Bakhtin AV, Zakora GI, Ardzha AYu, et al. Pokazateli kletochnogo immuniteta pri primenenii ingarona v kachestve terapii soprovozhdeniya pri rake yaichnikov. Rossiyskiy immunologicheskiy zhurnal. 2015; 1 (1): 141. Russian.
  37. Roberts AD, Ely KH, Woodland DL. Differential contributions of central and effector memory T cells to recall responses. J Exp Med. 2005 Jul 4; 202 (1): 123–33.